BioPharmica files patents for therapies using gene linked to Huntington's, AIDS

By Angela McDaniels

Seattle, Jan. 18 - BioPharmica Ltd. said that researchers from the Western Australian Institute for Medical Research have discovered a link between the HLS5 gene and key aspects of Huntington's disease and AIDS development.

The gene appears to be involved in several key regulatory processes within cells that have been shown to be important in susceptibility and progression for immune system regulation and neurodegenerative diseases such as Huntington's.

Additional studies found that the introduction of HLS5 reduced the formation of cancers in mice, the company said.

BioPharmica has lodged international patent protection over the involvement of HLS5 in these and additional diseases and said it will seek licensing and collaboration opportunities for use of the gene in the treatment of cancer, neurodegenerative and infectious diseases.

"BioPharmica will continue to focus on diagnostic and therapeutic applications in cancer with HLS5 with the Western Australian Institute for Medical Research," managing director Sam Gallagher said in a company news release.

BioPharmica is a biopharmaceutical company based Perth, Australia.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.